Cancer Check Labs Expands Multi-Cancer Detection Test to New York
The blood-based screening test can detect more than 200 types of solid tumor cancers and is now available in all 48 continental states.
The blood-based screening test can detect more than 200 types of solid tumor cancers and is now available in all 48 continental states.
The research‑use‑only test for post‑treatment breast cancer monitoring is now available through the company’s affiliate EG Biomed US.
Self-collection for HPV and other infections offers a more convenient, private way to complete recommended screenings—helping reach women who might otherwise delay or skip care.
German laboratory brings tumor-informed MRD testing to European market through licensing agreement with Quest Diagnostics subsidiary.
Read MoreNew automated workflow combines at-home sampling with robotic lab processing.
Read MorePartnership will bring Galleri multi-cancer early detection test to South Korea, with potential expansion to Japan and Singapore.
Read MoreNew skin tissue analysis tools aim to address diagnostic challenges in one of pathology’s most diverse specialties.
Read MoreOncoGenDx analyzes 335 DNA genes and 72 RNA genes using next-generation sequencing technology to support treatment decisions.
Read MorePROSTOX ultra identifies patients at higher risk of developing late genitourinary toxicity from stereotactic body radiation therapy.
Read MoreThe PRECEDE Consortium doubles its enrollment target to 20,000 as it builds a dataset for early detection tool development.
Read MoreStudy finds molecular signature identifies which men with recurrent disease respond to apalutamide plus salvage radiation therapy.
Read MoreThe new testing option detects 14 high-risk HPV strains without requiring pelvic examination, targeting patients 30 and older with no previous abnormal screenings.
Read MoreA new blood-based test that combines four protein markers with artificial intelligence has demonstrated potential for early lung cancer detection in a multicenter retrospective study.
Read MoreFirst Ascent Biomedical is validating a live-cell testing platform that screens over 150 FDA-approved therapies against a patient’s tumor, generating individualized treatment insights in about 10 days.
Read MoreThe company is collaborating with Guardant Health to make Guardant’s Shield test available through Quest’s nationwide network of provider clients and patient service centers.
Read MoreOn World Lung Day, Reveal Dx board member Mat Brevard discusses why current diagnostic tools fall short—and how new approaches could improve accuracy and outcomes.Â
Read MoreThe laboratory-developed test is used to detect and monitor metastatic central nervous system cancer.
Read MoreThe 2,400-patient study evaluates the Percepta Nasal Swab test’s ability to guide management decisions for patients with lung nodules.
Read More